Press Release

Mirum Pharmaceuticals Closes $120 Million Series A

Company also acquires rights to rare liver disease program from Shire
November 21, 2018

San Diego – November 21, 2018 – Cooley advised Mirum Pharmaceuticals on its $120 million Series A financing. Partners Jason Kent and Kay Chandler led the Cooley team advising Mirum.

New Enterprise Associates led the round, which also included participation by Deerfield Management, Frazier Healthcare Partners, Novo Holdings A/S, Pappas Capital, RiverVest Venture Partners and Rock Springs Capital.

The financing will support the development of Mirum’s lead drug candidate, maralixibat, for rare cholestatic liver diseases. In conjunction with the financing, Mirum has entered into an agreement with Shire for the exclusive global rights to develop and market maralixibat, as well as volixibat. Shire will receive an upfront payment, an equity position in Mirum and potential future milestone payments and royalties.

Mirum is a clinical-stage therapeutics company developing a novel approach for treating cholestatic liver diseases, with an immediate focus on rare pediatric conditions.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900+ lawyers across 13 offices in the United States, China and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.